Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

JW Therapeutics Completes $300 Million Hong Kong IPO for CAR-T Products

publication date: Nov 3, 2020

JW Therapeutics, a Shanghai cell therapy company, raised $300 million in its Hong Kong IPO at a market capitalization of $1 billion. In 2016, JW was founded as a JV between Juno Therapeutics of Seattle and WuXi AppTec to bring Juno's CAR-T candidates to China. The company's NDA for its lead candidate, an anti-CD19 CAR-T therapy, is under review in China as a third-line treatment for B-cell lymphoma. JW priced its IPO at HK$23.80, the top of the expected range, but it slipped to HK$22 in its first trading session. More details....

Stock Symbols: (HK: 2126) (SHA: 603259; HK: 2359)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.